133 related articles for article (PubMed ID: 19923785)
1. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Georgieva I; Koychev D; Wang Y; Holstein J; Hopfenmüller W; Zeitz M; Grabowski P
Neuroendocrinology; 2010; 91(2):121-30. PubMed ID: 19923785
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
3. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
4. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
5. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Kaestner P; Stolz A; Bastians H
Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
[TBL] [Abstract][Full Text] [Related]
6. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
[TBL] [Abstract][Full Text] [Related]
7. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
8. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
9. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.
Yoon MJ; Park SS; Kang YJ; Kim IY; Lee JA; Lee JS; Kim EG; Lee CW; Choi KS
Carcinogenesis; 2012 Mar; 33(3):492-500. PubMed ID: 22159225
[TBL] [Abstract][Full Text] [Related]
10. Validating Aurora B as an anti-cancer drug target.
Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts.
Gadea BB; Ruderman JV
Mol Biol Cell; 2005 Mar; 16(3):1305-18. PubMed ID: 15616188
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.
Vidarsdottir L; Steingrimsdottir G; Bodvarsdottir SK; Ogmundsdottir HM; Eyfjord JE
Invest New Drugs; 2012 Apr; 30(2):425-34. PubMed ID: 20960027
[TBL] [Abstract][Full Text] [Related]
13. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
Ditchfield C; Johnson VL; Tighe A; Ellston R; Haworth C; Johnson T; Mortlock A; Keen N; Taylor SS
J Cell Biol; 2003 Apr; 161(2):267-80. PubMed ID: 12719470
[TBL] [Abstract][Full Text] [Related]
14. ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture.
Long ZJ; Xu J; Yan M; Zhang JG; Guan Z; Xu DZ; Wang XR; Yao J; Zheng FM; Chu GL; Cao JX; Zeng YX; Liu Q
Cell Cycle; 2008 May; 7(10):1473-9. PubMed ID: 18418083
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
16. The Aurora kinase inhibitor ZM447439 accelerates first meiosis in mouse oocytes by overriding the spindle assembly checkpoint.
Lane SI; Chang HY; Jennings PC; Jones KT
Reproduction; 2010 Oct; 140(4):521-30. PubMed ID: 20660090
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells.
Sun L; Li D; Dong X; Yu H; Dong JT; Zhang C; Lu X; Zhou J
Biochem Pharmacol; 2008 Mar; 75(5):1027-34. PubMed ID: 18163976
[TBL] [Abstract][Full Text] [Related]
19. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).
Höpfner M; Sutter AP; Gerst B; Zeitz M; Scherübl H
Br J Cancer; 2003 Nov; 89(9):1766-75. PubMed ID: 14583782
[TBL] [Abstract][Full Text] [Related]
20. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.
Ikezoe T; Yang J; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2007 Jun; 6(6):1851-7. PubMed ID: 17541033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
